Seres Therapeutics, Inc.
NASDAQ:MCRBBiotechnology
+$0.11 today
- Market cap
- $51.13M
- Beta
- 0.11
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$4.89
Volume 0.04M
Average 0.06M
MCRB Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Seres Therapeutics, Inc.NASDAQ: MCRB
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares grows in line with its trailing trend
Q1 FY2026 weighted avg shares of 9.58M shares rose 10.1% year over year, in line with the +10.4% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 8.2% from the prior quarter. Over 3 fiscal years it compounded at +17.9% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +10.1% toward the trailing-twelve-month pace of +10.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 8.86M USD
- Year-over-year change
- +14.0%
- 4-year CAGR
- +17.9%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.86M | +14.0% |
| FY2024 | 2024-12-31 | 7.77M | +21.4% |
| FY2023 | 2023-12-31 | 6.4M | +18.4% |
| FY2022 | 2022-12-31 | 5.4M | +17.9% |
| FY2021 | 2021-12-31 | 4.59M | — |
Weighted Avg Shares vs competitors
How MCRB compares with its peers on the latest reported figures
- MCRB's LTM Mar 2026 weighted avg shares of 8.99M shares is the lowest of the 9 companies compared; the peer median is 59.1M shares.
- Its year-over-year change of +10.4% is the 6th highest of 9, against a peer median of +41.0%.
- Over three fiscal years its annual growth of +17.9% compares with a peer median of +25.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
IRDOpus Genetics, Inc. | LTM Mar 2026 | 406.29M | +1283.9% | +214.9% |
| LTM Mar 2026 | 312.72M | +1040.7% | +186.8% | |
| LTM Mar 2026 | 79.93M | +69.4% | +35.9% | |
| LTM Mar 2026 | 61.23M | +1.8% | +14.3% | |
| LTM Mar 2026 | 56.96M | -7.5% | -2.7% | |
| LTM Mar 2026 | 56.4M | +3.7% | +14.2% | |
| LTM Mar 2026 | 50.79M | +127.0% | +911.7% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | 21.96M | +12.5% | +11.8% |
| LTM Mar 2026 | 8.99M | +10.4% | +17.9% | |
| Peer median (excluding MCRB) | 59.1M | +41.0% | +25.1% | |
Competitors are the stored peer set for MCRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 144.93M | 0 | 0 | 0 | 789K |
| Cost of Revenue | 0 | 0 | 19.34M | 3.53M | 4.13M |
| Gross Profit | 144.93M | 0 | (19.34M) | (3.53M) | (3.34M) |
| Gross Margin | 100.0% | — | — | — | -423.8% |
| Research & Development | 141.89M | 109.65M | 117.6M | 64.6M | 49.06M |
| Selling, General & Admin | 69.26M | 70.26M | 77.5M | 53.18M | 39.16M |
| Operating Expenses | 209.42M | 179.91M | 175.76M | 117.78M | 90.63M |
| Depreciation & Amortization | 5.95M | 6.63M | 6.24M | 5.47M | 4.13M |
| EBITDA | (56.72M) | (170.93M) | (181.42M) | (120.3M) | 9.83M |
| EBITDA Margin | -39.1% | — | — | — | 1245.8% |
| Operating Income | (64.49M) | (179.91M) | (195.1M) | (121.32M) | (93.97M) |
| Operating Margin | -44.5% | — | — | — | -11910.1% |
| Interest Income | 2.87M | 3.06M | 7.3M | 3.97M | 2.23M |
| Interest Expense | 2.91M | 6.02M | 13.18M | 0 | 0 |
| Other Income / Expenses | (1.09M) | (3.67M) | 4.97M | (4.46M) | 99.67M |
| Income Before Tax | (65.58M) | (183.58M) | (190.13M) | (125.77M) | 5.7M |
| Pre-Tax Margin | -45.2% | — | — | — | 721.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (65.58M) | (250.16M) | (113.72M) | (146.57M) | 5.7M |
| Net Margin | -45.2% | — | — | — | 721.9% |
| EPS (Basic) | (14.30) | (46.29) | (17.77) | (18.86) | 0.64 |
| EPS (Diluted) | (14.30) | (46.29) | (17.77) | (18.86) | 0.64 |
| Weighted Avg Shares | 4.59M | 5.4M | 6.4M | 7.77M | 8.86M |
| Weighted Avg Shares (Diluted) | 4.59M | 5.4M | 6.4M | 7.77M | 8.87M |
Seres Therapeutics, Inc.
NASDAQ:MCRB
Intrinsic Alpha fair value
Locked
Current Price
$5.28
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.